IRIS
TIRIBELLI, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.290
EU - Europa 2.633
AS - Asia 1.087
AF - Africa 14
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 6
SA - Sud America 1
Totale 14.038
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.240
UA - Ucraina 866
CN - Cina 426
SG - Singapore 383
DE - Germania 360
IT - Italia 291
FI - Finlandia 265
RU - Federazione Russa 239
FR - Francia 173
IE - Irlanda 160
SE - Svezia 151
VN - Vietnam 111
TR - Turchia 98
CA - Canada 47
GB - Regno Unito 42
PL - Polonia 23
IN - India 21
IR - Iran 14
BE - Belgio 13
HK - Hong Kong 13
CZ - Repubblica Ceca 10
NL - Olanda 8
TG - Togo 8
EU - Europa 7
AT - Austria 6
EG - Egitto 6
ID - Indonesia 6
AU - Australia 5
ES - Italia 5
JP - Giappone 5
KR - Corea 5
BG - Bulgaria 4
CH - Svizzera 3
HU - Ungheria 3
DK - Danimarca 2
GR - Grecia 2
RO - Romania 2
AE - Emirati Arabi Uniti 1
BR - Brasile 1
CR - Costa Rica 1
GL - Groenlandia 1
IL - Israele 1
KZ - Kazakistan 1
LI - Liechtenstein 1
LT - Lituania 1
LU - Lussemburgo 1
MX - Messico 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
RS - Serbia 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 14.038
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.487
Fairfield 1.407
Houston 904
Ann Arbor 880
Ashburn 598
Jacksonville 578
Seattle 578
Chandler 551
Wilmington 494
Cambridge 467
Dearborn 395
Singapore 322
Boardman 240
Princeton 181
Beijing 173
Dublin 158
Dong Ket 110
Udine 105
Izmir 98
San Diego 82
Ogden 53
Des Moines 45
Norwalk 37
Nanjing 33
Ottawa 32
Hefei 28
New York 25
Phoenix 24
Warsaw 22
Guangzhou 21
Kunming 21
Dallas 18
Hangzhou 18
Helsinki 18
Trieste 17
Redmond 16
Brussels 13
Duino-Aurisina 13
Munich 13
Hong Kong 12
Los Angeles 12
Baton Rouge 10
Jinan 9
Milan 9
Simi Valley 9
Toronto 9
Andover 8
Fuzhou 8
Lomé 8
Santa Clara 8
Zanjan 8
Hyderabad 7
Nanchang 7
Shenyang 7
Brno 6
Cairo 5
Frankfurt am Main 5
Grafing 5
Hebei 5
Rome 5
Saint Petersburg 5
Shanghai 5
Tokyo 5
Washington 5
Florence 4
Lappeenranta 4
Ningbo 4
Sofia 4
Vienna 4
Zhengzhou 4
Amsterdam 3
Jakarta 3
Jiaxing 3
Jinhua 3
Leawood 3
London 3
Maserada Sul Piave 3
Montreal 3
Nanning 3
Nuremberg 3
Prague 3
Redwood City 3
Rovigo 3
Sacramento 3
Venezia 3
Wayne 3
Wuhan 3
Zurich 3
Athens 2
Augusta 2
Baotou 2
Barletta 2
Boston 2
Brugnera 2
Budapest 2
Cavaso del Tomba 2
Changzhou 2
Dolo 2
Dongguan 2
Edinburgh 2
Totale 10.559
Salva come PNG Salva come JPEG
Nome #
BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients 182
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. 157
Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology 147
Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. 147
Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma. 141
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors 138
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 134
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 133
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. 131
Histone post-translational modifications associated to BAALC expression in leukemic cells. 130
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. 130
Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib 129
Clinical feature and outcome in seven patients wuth hyaline or mixed variant of Castleman’s disease. A single centre experience 126
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 125
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 123
ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission 120
Differences among young adults, adults and elderly chronic myeloid leukemia patients. 117
Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells 116
Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. 114
All-trans retinoic acid (ATRA) potentiates the in vitro inhibitory effects of IFN-alpha in parental (32D) and p210-bcr/abl transfected (LG7) murine myeloid cell lines 113
ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome 112
Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias 111
Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia 111
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib 109
ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia 109
Unexpected phenotype of a typical NPM1 mutant 108
Nocardiosis with favourable clinical outcome in progressive B-chronic lymphocytic leukaemia 108
Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement 108
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 108
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 108
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis 108
A phase II study of α-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia 107
EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia. 106
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia 106
Impact of fludarabine-based induction therapy on outcome of FLT3-/NPM1+ cytogenetically normal acute myeloid leukemia. 106
Evaluation of residual CD34+ Ph+ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy 106
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 106
Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy. 105
The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. 105
High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients 105
Erratum: Functional regulation of the Apurinic/apyrimidinic endonuclease APE1 by Nucleophosmin (NPM1): Impact on tumor biology 104
Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera. 104
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 104
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. 104
Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia 103
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy 103
ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML 103
The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype 103
Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells 101
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia 101
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicinee—Results from the Italian ‘Back to Life’ project 101
Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib? 101
Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. 100
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib 100
How could patient reported outcomes improve patient management in chronic myeloid leukemia? 99
Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy 99
Q141K polymorphism of ABCG2 protein is associated with poor prognosis in adult acute myeloid leukemia treated with idarubicin-based chemotherapy. 98
The Sorafenib plus Nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of the FLT3 and p53 status. 98
Intensified full-dose induction therapy (HD-MACHOP+radiotherapy) follwed dy consolidation with BAVC regimen and autologous stem cell transplantation as fron-line therapeutic approach for high risk aggressive non Hodgkin lymphoma 97
Factors affecting outcome of allogeneic stem cell transplantation as salvage in patients with acute myeloid leukemia primary refractory to intensive induction therapy. 97
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 97
Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70 96
Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data 96
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) 96
Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. 96
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series 95
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients 94
CONCOMITANT BCRP OVER-EXPRESSION AND FLT3-ITD MUTATION IDENTIFY A SUBSET OF ACUTE MYELOID LEUKEMIA PATIENTS AT HIGH RISK OF RELAPSE 93
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 92
5-AZACITIDINE FIVE DAYS/MONTHLY SCHEDULE IN SYMPTOMATIC LOW-RISK (IPSS: 0-1) MYELODISPLASTIC (MDS) PATIENTS. CLINICAL AND BIOLOGICAL EFFECTS Authors 91
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 years treated with induction regimens including fludarabine: retrospective analysis of 224 cases 90
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib 90
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response. 88
Endogenous endophthalmitis following disseminated fungemia due to Fusarium solani in a patient with acute myeloid leukemia 87
FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience 86
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. 86
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. 85
The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts 84
WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia 84
Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy 84
EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations. 83
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 83
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy 82
A simple Prognostic Scoring System for newly diagnosed acute leukaemia patients with normal karyotype: a retrospective analysis on 173 cases. 81
Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. 81
Invasive fungal infections in allogneic haematopoietic stem cell transplantation: 12 years experience on 246 patients at a single institution 80
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients 80
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. 80
Pilot study of combined therapy with interferon-alpha, arabinosyl cytosine and all-trans retinoic acid in patients with chronic myeloid leukemia in the chronic phase 79
ABCB1 (PGP) and ABCG (BCRP) proteins are independent prognostic factors for complete remissione and relapse risk, respectively in normal karyotype adult de novo acute myeloid leukemia. 79
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 79
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 78
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 77
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 77
Reduced expression of cell cycle-associated genes in B lymphocytes purified from the peripheral blood of early-stage B chronic lymphocytic leukaemia patients. 76
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study. 76
The significance of early warning in chronic myeloid leukemia 76
Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse 76
A SIMPLE PROGNOSTIC SCORING SYSTEM FOR NEWLY DIAGNOSED ACUTE LEUKAEMIA PATIENTS WITH NORMAL KARYOTYPE: A RETROSPECTIVE ANALYSIS ON 420 CASES 75
Prognostic factors anad expression of multidrug-resistance related proteins in 36 patients with acute promyelocytic leukemia. 74
Totale 10.207
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.567
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.567
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.006 0 0 0 0 0 0 496 479 354 334 77 266
2020/20212.255 40 275 61 307 92 298 111 240 306 85 232 208
2021/20221.348 64 145 51 65 23 66 78 60 16 226 325 229
2022/20231.338 199 80 8 156 136 391 6 108 170 24 43 17
2023/2024474 65 48 11 24 52 38 8 49 76 38 24 41
2024/20251.004 79 251 113 141 125 141 154 0 0 0 0 0
Totale 14.489